

CURRICULUM VITAE

David Scott Saperstein, M.D.
Phoenix Neurological Associates
5090 N. 40th St. Suite 250
Phoenix, AZ 85018
Phone: 602-258-3354
Fax: 602-258-3368
E-mail: dsaperstein@pnal.net

PERSONAL:

Date of Birth:
June 1, 1966

Place of Birth:
Providence, RI

Marital Status:
Married - Francine N. Saperstein

EDUCATION:

Undergraduate:

Boston University 1984-1988
Boston, MA
Degree: BA, Biology
Summa cum laude with distinction in Biology

Medical School:

Boston University School of Medicine 1988-1992
Boston, MA
Degree: MD

POSTDOCTORAL TRAINING:

Internal Medicine Residency:

Wilford Hall USAF Medical Center 1992-1994
San Antonio, TX

Neurology Residency

Wilford Hall USAF Medical Center 1994-1997
San Antonio, TX

Neuromuscular Disease/Clinical Neurophysiology Fellowship

University of Texas Southwestern Medical Center 1997-1998
Dallas, TX

LICENSURE:

Arizona State Medical License # 34039	2005-present
Kansas State Medical License # 04-29601	2002-2005
Missouri State Medical License # 2002009374	2002-2005
Texas State Medical License # K4229	1997-2002
Pennsylvania State Medical License # MD-058627-L (inactive status 1999-present)	1996

BOARD CERTIFICATION:

American Board of Psychiatry and Neurology Certificate # 45963	1998
Added Qualifications in Clinical Neurophysiology Certificate # 1301	2001
American Board of Electrodiagnostic Medicine Certificate # 3047	2000

MILITARY SERVICE

U.S. Air Force, Active Duty Honorable Discharge; rank of Major	1992-2002
---	-----------

ACADEMIC APPOINTMENTS:

Assistant Professor Department of Neurology The University of Kansas Medical Center Kansas City, KS	2002-2005
Assistant Professor (secondary appointment) Department of Pathology and Laboratory Medicine University of Kansas Medical Center Kansas City, KS	2002-2005
Clinical Assistant Professor Department of Medicine/Division of Neurology University of Texas Health Science Center at San Antonio San Antonio, TX	1999-2002

POSITIONS HELD:

Chief, Neuromuscular Disease Service Department of Neurology The University of Kansas Medical Center Kansas City, KS	2003-2005
Staff Neurologist	2002-2005

Department of Neurology
The University of Kansas Medical Center
Kansas City, KS

Clerkship Director
Department of Neurology
The University of Kansas Medical Center
Kansas City, KS

Chief of Neuromuscular Services,
Director of Electromyography Laboratory
Department of Neurology
Wilford Hall USAF Medical Center
San Antonio, TX

Staff Neurologist, Muscular Dystrophy Association Clinic
University of Texas Health Science Center at San Antonio
San Antonio, TX

Residency Training Officer
Department of Neurology
Wilford Hall USAF Medical Center
San Antonio, TX

2002-2005

1998-2002

1999-2002

1999-2002

PROFESSIONAL MEMBERSHIPS:

Society of Air Force Physicians

1992-2002

American Academy of Neurology

1994- present

American Association of Electrodiagnostic Medicine

1997- present

World Muscle Society

1999- present

Texas Neurological Society

2000- 2002

Peripheral Nerve Society

2003-present

COMMITTEES:

National Committees:

Annual Meeting Workshop Committee American Association of Electrodiagnostic Medicine	2003-present
Medical Advisory Board, Charcot-Marie-Tooth Association	2004-present
Chairman, Education Committee ALS Research Group	2005-present

Local Committees:

Ad Hoc Committee on Medical Student Education University of Texas Health Science Center at San Antonio	1999-2002
Selection Committee, Texas Neurological Society's Young Investigator's Award	2000-2002
Medical Student Education Committee, Chairman Department of Neurology, KUMC	2002-2005
Research Committee Department of Neurology, KUMC	2002-2005
Curriculum Committee, Long-term Planning University of Kansas School of Medicine	2003-2004
GCRC Planning Committee University of Kansas Medical Center	2003-2004
Dean's Pediatric Chair and Department Review Committee, Vice-Chairman University of Kansas Medical Center	2004
LCME Committee University of Kansas School of Medicine	2004-2005

RESEARCH GROUP MEMBERSHIPS

Muscle Study Group	1998-present
Western ALS Study Group	1998-present
American ALS Research Group	2003-present
Northeast ALS Research Group	2005-present

WORKSHOP PARTICIPATION:

Bone Quality in Duchenne Muscular Dystrophy, July 8, 2004.
Sponsored by the Parent Project in Muscular Dystrophy.

HONORS AND AWARDS:

Boston University Trustee Scholar	1984-1988
Phi Beta Kappa Honor Society	1988
Alpha Omega Alpha Honor Society	1992
American Academy of Neurology Resident Teaching Award	1997
Neurophysiology Faculty Teaching Award, KUMC	2004

GRANT SUPPORT:

Co-investigator (R. Tawil, P.I.), Inclusion Body Myositis: A Pilot Study of Beta Interferon-1A. NIH (R01-NS38585-01). \$37,500; 7/99-6/02.

Co-Investigator (Merit E. Cudkowicz MD, PI) A Clinical Trial of Celebrex in subjects with ALS. To determine if Celebrex slows down the progression of ALS. Funded by John Hopkins University via Muscular Dystrophy Association & Pharmacia Corp.

Co-Investigator (Jeffery Rosenfeld MD, PI) A Clinical Trial of Creatine in ALS. To determine if Creatine slow down the progression of ALS. Funded by FDA ODG # RO-1At00967-01A1

Co-Investigator (Donald B. Sanders, P.I) A Clinical Trial of Mycophenolate Mofetil in Myasthenia Gravis. To determine if Mycophenolate slows down the progression of Myasthenia Gravis. Funded by FDA-OPD #FDA-R-002154, 4/1/2002 – 3/31/2005 and Roche Pharmaceutical Co. Grant CEL 248, 7/1/2002 – 6/30/2005.

Co-Investigator (Paul H. Gordon MD, PI) A Clinical Trial of Minocycline in subjects with ALS. To determine if Minocycline slows down the progression of ALS. Funded by NIH/NINDS # R01 NS045294-01

Co-investigator (Steven Greenberg MD, PI) Gene Expression in Inflammatory Myopathies study. To gain a better understanding of gene expression in various inflammatory myopathies. Funded by the National Institute of Health. Funded by NINDS Grant # R01 NS043471-01A1 \$2000/year; 12/1/02 – 11/30/05

Co-Investigator (Jerry Mendell MD, PI) Six Month (26 Weeks) Double Blind, Randomized, Clinical Trial Of Gentamicin In Duchenne Muscular Dystrophy Subjects With Stop Codon Mutations. To determine if gentamicin can increase muscle dystrophin production in patients with selected dystrophin mutations. Funded by NIH # OSU 01HO265

Principal investigator. Clinical Trial Of Gentamicin in Duchenne Muscular Dystrophy Subjects With Stop Codon Mutations. To determine if gentamicin can increase muscle dystrophin production in patients with selected dystrophin mutations. Funded by the Muscular Dystrophy Association # MDA3724. \$52,212; 1/1/04-12/31/05.

Co-Investigator (supported trainee) (Robert Griggs MD, PI). Consortium in Neurologic Channelopathies (CINCH). To establish a network to study rare neurologic channelopathies. NIH/NCRR 1U54RR019482-01.

Co-Investigator (John T. Kissel MD, PI) A clinical trial of albuterol and oxandrolone in facioscapulohumeral (FSH) dystrophy. To determine if albuterol and oxandrolone alone or in combination slows the progress of FSH Dystrophy. FDA-ODG - # FDA-R-002029-01

Co-Investigator (Rick T. Dobrowsky, Ph.D., PI) Proteomic approaches to diabetic neuropathy. J.R. & Inez Jay Fund – University of Kansas

Co-investigator (Ellen Vernotica, Ph.D. Global Clinical Trial Leader) Study of TCH346 versus placebo for ALS. Novartis Pharmaceuticals. To determine if TCH346 can slow progression of ALS.

Co-Investigator (Carlayne Jackson MD, PI) A randomized, double-blind, placebo-controlled study of safety and efficacy of botulinum toxin type B (myobloc) for sialorrhea in amyotrophic lateral sclerosis. To assess the benefit of botulinum toxin B in treated ALS-related sialorrhea. Amyotrophic Lateral Sclerosis Association (ALSA).

Co-Investigator (Robert Griggs MD, PI) Dichlorphenamide vs acetazolamide for periodic paralysis. To determine which treatment is superior for periodic paralysis. 1 RO1 NS045686-01A1. 2/1/04 - 1/31/09.

Co-Investigator (Jeanne Drisko MD, PI) Intravenous glutathione for amyotrophic lateral sclerosis. To determine if the antioxidant glutathione can significantly slow the progression of ALS. Private funding source.

Co-P.I. (Douglas Wright, Co-P.I.). Cutaneous innervation in human diabetic neuropathy. To study the role of different nerve fiber types in peripheral neuropathy pain. Leid Endowed Basic Science Pilot Research Grant. \$35,000.

Co-Investigator. A randomized, double-blind, placebo controlled, dose-ranging study to determine the efficacy of Avonex when used in subjects with chronic inflammatory demyelinating polyneuropathy. To determine if Avonex therapy will allow IVIg to be discontinued. Biogen Protocol C-870.

Co-Investigator. IMPACT: Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IGIV-Chromatography (IGIV-C), 10% treatment in patients with Chronic inflammatory demyelinating polyneuropathy. To determine if IGIV-C is a safe and effective treatment for CIDP. Bayer Protocol # 100538.

Co-Investigator. A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 36-week trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve symptom control with reduced corticosteroids in subjects with myasthenia gravis. Protocol # WX17798. Sponsor: F Hoffmann-La Roche Ltd/Inc/AG as part of the Aspreva Pharmaceuticals Corp. Rare Disease Program.

Co-Investigator. A double-blind, placebo controlled, randomized, multiple ascending dose, safety study of MYO-029 administered to adult patients with Becker, facioscapulohumeral and limb-girdle muscular dystrophy. Wyeth Protocol # 3147K2-101-WW.

Co-Investigator (Petra Kaufmann MD, PI) A Clinical Trial of high-dose coenzyme Q10 in subjects with ALS. To determine if coenzyme Q10 slows down the progression of ALS. Funded by NIH/NINDS 1RO1 NS 048125-01.

Co-Investigator (Merit E. Cudkowicz MD, PI) A Clinical Trial of Ceftriaxone in Subjects with ALS. To determine if coenzyme Q10 slows down the progression of ALS. Funded by NIH/NINDS 1RO1

AD HOC REVIEWING:

Archives of Neurology

Expert Opinion on Pharmacotherapy

Muscle & Nerve

Neurology

PUBLICATIONS:

Journal Publications:

1. Wolfe GI, Baker NS, Amato AA, Jackson CE, Nations SP, **Saperstein DS**, Cha C, Bryan WW, Barohn RJ. Cryptogenic sensory polyneuropathy: clinical and electrophysiologic characteristics. *Arch Neurol* 1999;56:540-547.
2. **Saperstein DS**, Amato AA, Wolfe GI, Katz JS, Nations SP, Bryan WW, Burns DK, Barohn RJ. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. *Muscle Nerve* 1999;22:560-566.
3. Katz JS, Wolfe GI, Andersson PB, **Saperstein DS**, Elliott JL, Nations SP, Bryan WW, Barohn RJ. Brachial amyotrophic diplegia: a slowly progressive motor neuron disorder. *Neurology* 1999;53:1071-1076.
4. Katz JS, **Saperstein DS**, Gronseth GS, Amato AA, Barohn RJ. Distal acquired demyelinating symmetrical neuropathy. *Neurology* 2000;54:615-620.
5. **Saperstein DS**, King RB. Motor neuron presentation of a deep ulnar branch neuropathy with a Riche-Cannieu anastomosis. *Electromyogr Clin Neurophys* 2000;40:119-122.
6. **Saperstein DS**, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. *Muscle Nerve* 2001;24:311-324.
7. Katz JS, **Saperstein DS**, Wolfe G, Nations SP, Alkhersam H, Amato AA, Barohn RJ. Cervicobrachial involvement in diabetic radiculoplexopathy. *Muscle Nerve* 2001;24:794-798.
8. **Saperstein DS**, Amato AA, Barohn RJ. Clinical and genetic aspects of distal myopathies. *Muscle Nerve* 2001;24:1440-1450.
9. Katz JS, Barohn RJ, Kojan S, Wolfe GI, Nations SP, **Saperstein DS**, Amato AA. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. *Neurology* 2002;58:615-620.

10. **Saperstein DS**, Wolfe GI, Gronseth GS, Nations SP, Herbelin LL, Bryan WW, Barohn RJ. Challenges in the identification of cobalamin-deficiency polyneuropathy. *Arch Neurol* 2003;60:1296-301.
11. Katz JS, Rando TA, Barohn RJ, **Saperstein DS**, Jackson CE, Wicklund M, Amato AA. Late-onset distal muscular dystrophy affecting the posterior calves. *Muscle Nerve* 2003;28:443-448.
12. The Muscle Study Group (Tawil R, Griggs R, Thornton C, Kissel J, Mendell J, Genge A, Karpati G, Jackson C, Rose M, Amato A, Barohn R, **Saperstein D**). Randomized pilot trial of high-dose β INF-1a in patients with inclusion body myositis. *Neurology* 2004;63:718-720.
13. Sansone V, **Saperstein DS**, Barohn RJ, Meola G. Concurrence of facioscapulohumeral muscular dystrophy and myasthenia gravis. *Muscle Nerve* 2004;30:679-80.
14. Grogan, PM, Tanner SM, Ørstavik KH, **Saperstein DS**, Vogel H, Barohn RJ, Herbelin LL, McVey AL, Katz JS. Limb girdle myopathy with skeletal asymmetry and hemidiaphragm elevation: mutations in the myotubularin gene causing a novel myopathy phenotype. *Neurology* (in press).
15. Grogan PM, **Saperstein DS**, Barohn RJ, Cassini P, So Y, Katz JS. Electrodiagnostic findings in clinically-defined diabetic amyotrophy and diabetic-chronic inflammatory demyelinating polyneuropathy (submitted for publication).
16. Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, **Saperstein DS**, Barohn RJ, Tawil T, Burleson T, Due B, Slaney M, Hafler DA, Bregoli L, O'Connor KC, Amato AA. Plasma Cells in Muscle in Inclusion Body Myositis and Polymyositis (submitted for publication).
17. **Saperstein DS**, Wolfe GI, Longeria O, Herbelin LL, Nations SP, Jackson CE, Bryan WW, Barohn RJ. Quantitative sensory testing in a large cohort of neuropathy patients (in preparation).
18. **Saperstein DS**, Jackson CE, Herbelin LL, McVey AL, Barohn RJ, Katz JS. The numb hand syndrome: a focal myelopathy secondary to cobalamin deficiency (in preparation).

Editorials:

1. Yuki N, **Saperstein DS**. Axonal Guillain-Barre syndrome subtypes: Do we need more splitting? *Neurology* 2003;61:598-599.

Review Articles:

1. Barohn RJ, **Saperstein DS**. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. *Semin Neurol* 1998;18:49-61.
2. Katz JS, **Saperstein DS**. Asymmetric acquired demyelinating polyneuropathies: MMN and MADSAM. *Current Treatment Options in Neurology* 2001;3:119-125.
3. **Saperstein DS**, Barohn RJ. Peripheral neuropathy due to cobalamin deficiency. *Current Treatment Options in Neurology* 2002;4:197-201.

4. **Saperstein DS**, Barohn RJ. Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy. *Current Neurology and Neuroscience Reports* 2003;3:57–63.
5. Katz JS, **Saperstein DS**. Chronic Inflammatory Demyelinating Polyneuropathy. *Curr Treat Options Neurol* 2003;5:357-364.
6. **Saperstein DS**. Multifocal motor neuropathy: Diagnosis and treatment. *Advances in Immunotherapy* 2003;10:14-18.
7. **Saperstein DS**, Barohn RJ. Management of myasthenia gravis. *Semin Neurol* 2004;24:41-48.

Abstracts:

1. **Saperstein DS**, King RB. Motor neuron presentation of a deep ulnar branch neuropathy with a Riche-Cannieu anastomosis. *Muscle Nerve* 1996;19:1200.
2. **Saperstein DS**, Gronseth GS. Cost-effectiveness analysis of echocardiography in stroke patients without cardiac risk factors. *Neurology* 1998;50 (Suppl 4):A446.
3. Iannaccone SI, **Saperstein DS**, Delgado M, Sparagana S. Childhood chronic inflammatory demyelinating polyneuropathy: clinical and laboratory features. *Neurology* 1998;50 (Suppl 4):A143-144.
4. Nations SP, **Saperstein DS**, Wolfe GI, Bryan WW, Barohn RJ. Clinical profile of vitamin B12 neuropathy. *Neurology* 1998;50 (Suppl 4):A208-209
5. **Saperstein DS**, Herbelin L, Bryan WW, Barohn RJ. 3,4-Diaminopyridine in the treatment of Lambert-Eaton Myasthenic Syndrome. *J Child Neurol* 1998;13:134-135.
6. **Saperstein DS**, Iannaccone SI, Brumback RA, Delgado M, Sparagana S. Relapsing acute Guillain-Barré syndrome: clinical, electrophysiologic and pathologic features. *J Child Neurol* 1998;13:136-137.
7. van der Sluis RW, **Saperstein DS**, Barohn RJ, Bryan WW. Chronic inflammatory demyelinating polyneuropathy in a patient with inherited demyelinating polyneuropathy. *J Child Neurol* 1998;13:137.
8. **Saperstein DS**, Amato AA, Katz JS, Wolfe GI, Nations SP, Jackson CE, Bryan WW, Barohn RJ. Multifocal sensory and motor neuropathy differs from multifocal motor neuropathy. *Muscle Nerve* 1998;21:1589.
9. **Saperstein DS**, Collins MP, Wolfe GI, Nations SP, Haller RG, Burns DK, Bryan WW, Barohn RJ. Hepatitis C virus infection and inflammatory myopathy. *Neurology* 1999;52 (Suppl 2):A451-A452.
10. **Saperstein DS**, Katz JS, Gronseth GS, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy and its distinction from CIDP. *Neurology* 2000;54 (Suppl 3):A384-A385.
11. Katz JS, Amato AA, **Saperstein DS**, Kojan S, Burns D, Nations S, Wolfe GI, Barohn RJ. Multifocal acquired axonal motor neuropathy. *Neurology* 2001;56(Suppl 3):A397.

12. **Saperstein DS**, Jackson CE, Nations SP, Wolfe GI, Barohn RJ. Uncommon neurologic manifestations of pernicious anemia with cobalamin deficiency. *Neurology* 2001;56(Suppl 3):A417.
13. **Saperstein DS**, Wolfe GI, Longeria O, Herbelin LL, Nations SP, Jackson CE, Bryan WW, Barohn RJ. Quantitative sensory testing in a large cohort of neuropathy patients. *Muscle Nerve* 2001;24:1417-1418.
14. **Saperstein DS**, Wolfe GI, Nations SP, Herbelin LL, Barohn RJ. Electrodiagnostic features of cobalamin deficiency polyneuropathy. *Muscle Nerve* 2002;26:574.
15. Marky B, Herbelin LL, **Saperstein DS**, Barohn RJ. Electrodiagnostic abnormalities in patients with syringomyelia. *J Child Neurol* 2003;18:212.
16. Barohn RJ, McVey AL, Herbelin LL, **Saperstein D**. Myotonic dystrophy and facioscapulohumeral muscular dystrophy in the same patient. *J Child Neurol* 2003;18:207.
17. Ali H, McVey AL, **Saperstein DS**, Herbelin L, Whitakker TJ, Fitzgerald K, Barohn RJ, So YT, Katz JS, Grogan PM. Bilateral optic nerve atrophy or papilledema with chronic inflammatory demyelinating polyneuropathy and serum paraprotein. *J Child Neurol* 2003;18:215.
18. Herbelin L, Lian G, Gronseth G, Wolfe G, Bryan W, Nations S, **Saperstein D**. Two point stimulation sensory conduction studies in normal nerves. *Muscle Nerve* 2003;Supplement 12:S69.
19. **Saperstein DS**, McVey AL, Herbelin LL, Newell K, Barohn RJ. Pain and weakness in a patient on a statin medication: It's not always the statin. *J Child Neurol* 2004;19:204.
20. Herbelin L, Barohn RJ, McVey AL, **Saperstein DS**. A case of deep ulnar neuropathy at the wrist. *J Child Neurol* 2004;19:204.
21. Kumar S, **Saperstein D**, Herbelin L, Barohn RJ. Guillain-Barre syndrome in a patient with human erlichiosis infection. *J Child Neurol* 2004;19:206.
22. Wang Y. Barohn RJ, McVey AL, Newell K, Herbelin LL, **Saperstein DS**. Necrotizing myopathy: a unique immune-mediated myopathy. *J Child Neurol* 2004;19:207.
23. **Saperstein DS**, Grogan PM, Milford C, McVey AL, Wolfe GI, Nations SP, Herbelin LL, Barohn RJ, Skikne B, Vogel H, Katz JS. Myeloneuropathy in the setting of myelodysplastic syndrome. *Neurology* 2004;62(Suppl 5):A196.
24. Pasnoor M, McVey AL, Herbelin LL, Fishback JL, Barohn RJ, **Saperstein DS**. Anti-Hu antibodies and sensorimotor polyneuropathy associated with carcinoid tumorlet of lung. *Ann Neurol* 2004;56(Suppl 8):S60.
25. Herbelin LL, Drisko J, Barohn RJ, **Saperstein DS**, McVey AL, Khosh D, Dick A, Gronseth GS. Intravenous glutathione in ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders* 2004;5(Suppl 2):117.

26. Alseoudi S, Anderson H, Herbelin L, Barohn RJ, McVey AL, **Saperstein DS**. Comparison of the Sensitivity of Diagnostic Criteria for Chronic Inflammatory Demyelinating Polyneuropathy. *J Child Neurol* 2005;20:271.
27. Rashid I, **Saperstein DS**, McVey AL, Herbelin L, Skikne B, Barohn RJ. Rituximab for the treatment of IgM-Associated Polyneuropathies. *J Child Neurol* 2005;20:269.
28. Herbelin L, Barohn RJ, Mendell JR, McVey AL, Kissel JT, King W, **Saperstein DS**. Trial of Etanercept (Enbrel) in the Treatment of Inclusion Body Myositis (IBM). *J Child Neurol* 2005;20:269.

Book Chapters:

1. **Saperstein DS**, Wolfe GI. Corticosteroid myopathies. In: Gilman S, Goldstein GW, Waxman SG, editors. *Neurobase*. San Diego: Arbor Publishing. Revised 1999, 2000, 2001, 2003, 2004.
2. **Saperstein DS**, Wolfe GI. Myopathies associated with thyroid disease. In: Gilman S, Goldstein GW, Waxman SG, editors. *Neurobase*. San Diego: Arbor Publishing. Revised 1999, 2000, 2001, 2003, 2004.
3. Barohn RJ, **Saperstein DS**. Acute and Chronic Inflammatory Demyelinating Polyneuropathy. In: Younger DS (ed.). *Textbook of Motor Disorders*. Philadelphia: Lippincott Williams & Wilkins 1999.
4. **Saperstein DS**. Inclusion Body Myositis. In: Gilman S, Goldstein GW, Waxman SG (eds.). *Neurobase*. San Diego: Arbor Publishing. Revised 2000, 2001, 2002, 2003, 2004.
5. **Saperstein DS**. Viral and Retroviral Myositis. In: Gilman S, Goldstein GW, Waxman SG (eds.). *Neurobase*. San Diego: Arbor Publishing. Revised 2000, 2001, 2003, 2004.
6. **Saperstein DS**, Katz JS, Amato AA, Barohn RJ. Chronic Acquired Demyelinating Polyneuropathies. In: Sinha KK, Chandra P (eds.). *Advances in Clinical Neurosciences 10*. Ranchi, India: The Catholic Press; 2000: 187-206.
7. **Saperstein DS**, Amato AA, Katz JS, Barohn RJ. Immune Mediated Polyneuropathies. In: Pourmand R (ed.). *Neuromuscular Diseases: Expert Clinicians' Views*. Boston: Butterworth-Heinemann; 2001: 135-198.
8. **Saperstein DS**, Barohn RJ. Distal Myopathies. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE (eds.). *Neuromuscular Disorders in Clinical Practice*. Boston: Butterworth-Heinemann; 2002: 1092-1100.
9. **Saperstein DS**, Barohn RJ. Myasthenia Gravis. In: Rakel RE, Bope ET (eds.). *Conn's Current Therapy*. Philadelphia: W.B. Saunders Company; 2002: 937-942.
10. **Saperstein DS**. Distal myopathies. In: Gilman S, Goldstein GW, Waxman SG (eds.). *Neurobase*. San Diego: Arbor Publishing. Revised 2003, 2004.

11. **Saperstein DS**, Barohn RB. Polyneuropathy due to nutritional and vitamin deficiency. In: Dyck PJ, Thomas PK, eds. *Peripheral Neuropathy*, 4th ed. Philadelphia: Elsevier Saunders; 2005: 2051-2062.

Monographs:

Kissel JT, Amato AA, Barohn RJ, Iannaccone ST, Lange DJ, Mendell JR, **Saperstein DS**. Muscle Disease. CONTINUUM: Lifelong Learning in Neurology, Volume 6. Philadelphia: Lippincott Williams & Wilkins; 2000.

INVITED LECTURES:

1. "Guillain-Barré Syndrome and Related Disorders." Guillain-Barré Syndrome Foundation International Support Group Meeting, San Antonio, TX, May 1, 1999.
2. "Demyelinating Neuropathies." Clinical Neurology Update 1999 (Army Medical Education Department), San Antonio, TX, November 17, 1999.
3. "The Dizzy Patient." 3rd Annual Fiesta CME Conference, Society of Air Force Physician Assistants, San Antonio, TX, November 2, 2000.
4. "Identifying The Treatable Neuropathy Patient." Clinical Neurology Update 2002 (Army Medical Education Department), San Antonio, TX, November 21, 2002.
5. "Diagnosis and Management of Hereditary Neuropathies." Neurology Grand Rounds, The University of Arizona Health Science Center, Tucson, AZ, October 29, 2004.

COURSE INSTRUCTION:

1. "Multifocal Motor Neuropathy." Course 1KP.002: The Spectrum of Chronic Demyelinating Polyneuropathy. 52nd Annual Meeting of the American Academy of Neurology, San Diego, CA, April 29, 2000.
2. "Multifocal Motor Neuropathy." Course 1KP.002: The Spectrum of Chronic Demyelinating Polyneuropathy. 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, PA, May 5, 2001.
3. "Multifocal Motor Neuropathy." Course 2BS.008: The Spectrum of Chronic Demyelinating Polyneuropathy. 54th Annual Meeting of the American Academy of Neurology, Denver, CO, April 14, 2002.
4. "Approach To The Patient With Muscle Cramps And Fatigue." Course 8AC.004: Clinical Approach to muscle Disease. 54th Annual Meeting of the American Academy of Neurology, Denver, CO, April 20, 2002.
5. "CIDP and MADSAM" and "Pure Motor Neuropathies." Course 7DS.007: Common and Uncommon Phenotypes in Neuromuscular Disease. 55th Annual Meeting of the American Academy of Neurology, Honolulu, HI, April 4, 2003.

6. "Pure Motor Neuropathies." Course 2DS.008: Common and Uncommon Phenotypes in Neuromuscular Disease. 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, April 25, 2004.
7. "Cardiac, Pulmonary, and Muscle Complications of Myopathies." Course 8AC.002: Clinical Approach to Muscle Disease. 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, May 1, 2004.
8. "Outcome Measures in Clinical Neuromuscular Disease Trials." Course D: Clinical Research Design in Electrodiagnostic Medicine. 51st Annual Meeting of the American Association of Electrodiagnostic Medicine, Savannah, GA, November 4, 2004.
9. "Pure Lower Motor Neuron Syndromes." Course E: When It's Not ALS! Pure Motor Syndromes. 51st Annual Meeting of the American Association of Electrodiagnostic Medicine, Savannah, GA, November 4, 2004.
10. Moderator: Biopsy and EMG Session, 27th Annual Carrel-Krusen Neuromuscular Symposium, Dallas, TX February 24, 2005.
11. Course Director: "Peripheral Neuropathy", 57th Annual Meeting of the American Academy of Neurology, Miami, FL, April 10, 2005.
12. "Selecting Laboratory Tests in the Peripheral Neuropathy Patient", 57th Annual Meeting of the American Academy of Neurology, Miami, FL, April 10, 2005.
13. "Numb Feet and Other Peripheral Neuropathy Presentations." Common and Uncommon Phenotypes in Neuromuscular Disease. 57th Annual Meeting of the American Academy of Neurology, Miami, FL, April 10, 2005.

SCIENTIFIC PRESENTATIONS: (no published abstract)

1. "Emery-Dreifus Myopathy: Clinical and Immunohistochemical Features." 20th Annual Carrel-Krusen Symposium, Texas Scottish Rite Hospital for Children, Dallas, TX, February 27, 1998.
2. "Granulomatous Myositis in Association with Ovarian Cancer." Unusual Diagnostic and Management Problems in Neuromuscular Disease Seminar, 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN, May 1, 1998.
3. "A Case of Multifocal Acquired Demyelinating Sensory and Motor Neuropathy." Challenging EDX Cases Seminar, 45th Annual Meeting of the American Association of Electrodiagnostic Medicine, Orlando, FL, October 14, 1998.
4. "Nitrous Oxide-Induced Vitamin B12 Myeloneuropathy." Unusual Diagnostic and Management Problems in Neuromuscular Disease Seminar, 52nd Annual Meeting of the American Academy of Neurology, San Diego, CA, May 1, 2000.
5. "Myopathy and Cramps in a Patient on a Statin Drug." Unusual Diagnostic and Management Problems in Neuromuscular Disease Seminar, 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, April 26, 2004.

LOCAL INSTITUTION TALKS:

Grand Rounds:

1. "Multifocal Motor Neuropathy: Past, Present, and Future." Neurology Grand Rounds, University of Texas Health Science Center at San Antonio, December 10, 1999.
2. "Management of Patients Following TIA or Mild Stroke: Current Concepts and Controversies." Internal Medicine Grand Rounds, Wilford Hall Medical Center, March 12, 1999.
3. "Cost-Effectiveness Analysis of Echocardiography in Stroke Patients." Neurology Grand Rounds, University of Texas Health Science Center at San Antonio, June 24, 1999.
4. "Neuromuscular Pearls and Pitfalls." Neurology Grand Rounds, University of Texas Health Science Center at San Antonio, January 20, 2000.
5. "The Peripheral Neuropathy Patient: What Tests to Order?" Neurology Grand Rounds, University of Texas Health Science Center at San Antonio, December 14, 2000.
6. "Identifying The Treatable Neuropathy Patient." Neurology Grand Rounds, University of Kansas Medical Center, December 13, 2002.
7. "The Patient with an Elevated CK." Neurology Grand Rounds, University of Kansas Medical Center, October 17, 2003.

CLINICAL RESEARCH STUDIES

Investigator for the following:

Protocol # Biogen 101MS 402 for MS
Protocol #Teva Bravo for MS
Protocol #Lilly HMEF for MS
Protocol #Merck Musi Qo1 for MS
Protocol #Roche/Genentech olcrizimab for MS
Protocol #Medimmune CP 151 for dermatomyositis/polymyositis
Protocol #David Saperstein. Lithium for inclusion body myositis
Protocol #Cytex. Arimoclomol for ALS
Protocol #Mass General. Ceftriaxone for ALS
Protocol #T-GEN. Tretinoin for ALS
Protocol #Schering-Plough TIMI 50 for post-stroke
Protocol #Genzyme MTAP. Myozyme for Pompe
Protocol #J&J 333369 NPP 2002 for diabetic peripheral neuropathy
Protocol #Genentech. RIM study for dermatomyositis
Protocol #Teva. ASSERT TNC GA for multiple sclerosis
Protocol #Columbia University. Selection for ALS
Protocol #MDA T-Gen for ALS
Protocol #Teva NABS PM 208 for multiple sclerosis
Protocol #PalmMag Device for diabetic neuropathy
Protocol #Biogen Stratta for multiple sclerosis
Protocol #Lilly HMEZ for diabetic neuropathy
Protocol #Lilly HMDY for diabetic neuropathy
Protocol # Biogen 101MS 402 for MS
Protocol #Teva Bravo for MS
Protocol #Lilly HMEF for MS
Protocol #Merck Musi Qo1 for MS

Protocol #Roche/Genentech olcrizimab for MS
Protocol #Medimmune CP 151 for dermatomyositis/polymyositis
Protocol #David Saperstein. Lithium for inclusion body myositis
Protocol #Cytex. Arimoclomol for ALS
Protocol #Mass General. Ceftriaxone for ALS
Protocol #T-GEN. Tretinoin for ALS
Protocol #Schering-Plough TIMI 50 for post-stroke
Protocol #Genzyme MTAP. Myozyme for Pompe
Protocol #J&J 333369 NPP 2002 for diabetic peripheral neuropathy